Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable
one-year clinical benefit
Global registrational trial to enroll approximately 160 adults with HP to support once-weekly
canvuparatide’s potential as a best-in-class PTH replacement therapy
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)
/A%20close-up%20of%20the%20Broadcom%20logo%20on%20a%20smartphone%20by%20Timon%20via%20Adobe%20Stock.jpeg)